PUBLISHER: BIS Research | PRODUCT CODE: 2029915
PUBLISHER: BIS Research | PRODUCT CODE: 2029915
Europe Transgenic Animal Model Market: Focus on Technology, Animal Type, Application, End User, and Country - Analysis and Forecast, 2025-2035
This report can be delivered in 2 working days.
Market Overview
The Europe transgenic animal model market is experiencing steady growth, driven by increasing demand for advanced preclinical research tools, rising investments in biotechnology, and expanding applications in drug discovery and genetic research. Transgenic animal models play a critical role in understanding disease mechanisms and developing targeted therapeutics. The global transgenic animal model market is expected to witness significant growth during the forecast period 2025-2035, with Europe emerging as a key regional contributor due to strong research infrastructure and regulatory support. Countries such as Germany, the U.K., and France are at the forefront, fostering innovation in genetic engineering and biomedical research. The Europe transgenic animal model market is projected to reach $2,234.7 million by 2035 from $906.5 million in 2025, growing at a CAGR of 9.44% during the forecast period 2025-2035.
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2025 - 2035 |
| 2025 Evaluation | $906.5 Million |
| 2035 Forecast | $2,234.7 Million |
| CAGR | 9.44% |
Market Introduction
The Europe transgenic animal model market represents a vital segment of the life sciences and biotechnology industry, focusing on genetically modified animals that carry foreign genes inserted into their genome. These models are widely used in biomedical research to study gene function, disease progression, and therapeutic responses. Transgenic animal models, particularly mice and rats, have become indispensable tools in preclinical research, enabling scientists to replicate human disease conditions with high accuracy.
In Europe, the demand for transgenic animal models is being driven by increasing research activities in genomics, oncology, neurology, and rare diseases. The region's strong academic and research ecosystem, supported by government funding and collaborations with pharmaceutical and biotechnology companies, is accelerating the adoption of advanced genetic engineering technologies such as CRISPR/Cas9 and gene editing platforms.
Moreover, the rising focus on personalized medicine and targeted therapies is further boosting the need for precise and reliable animal models. Regulatory frameworks in Europe ensure ethical use and standardization, promoting high-quality research practices. Additionally, the presence of leading research institutions and biotech firms is fostering innovation and commercialization of transgenic animal models.
As the demand for efficient drug development and disease modeling grows, the Europe transgenic animal model market is poised for significant expansion, supported by technological advancements and increasing R&D investments.
Market Segmentation:
Segmentation 1: By Technology
- CRISPR/CAS-9
- Microinjections
- Embryonic Stem Cell Injections
- Others
Segmentation 2: By Animal Type
- Rodent (Mice & Rats)
- Rabbits
- Pigs
- Others
Segmentation 3: By Application
- Drug Discovery and Development
- Disease Research
- Gene Function Studies
- Toxicology and Safety Testing
- Others
Segmentation 4: By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
Segmentation 5: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
Market Trends, Drivers, and Challenges
Market Trends
- Increasing adoption of CRISPR/Cas9 and gene-editing technologies
- Growing focus on personalized medicine and targeted therapies
- Expansion of transgenic models for rare and complex diseases
- Rising collaborations between academic institutions and biotech firms
Market Drivers
- Growing demand for advanced preclinical models in drug discovery
- Increasing R&D investments in biotechnology and life sciences
- Rising prevalence of chronic and genetic diseases
- Strong regulatory frameworks supporting biomedical research
Market Challenges
- Ethical concerns regarding animal testing and genetic modification
- High cost and complexity of developing transgenic models
- Stringent regulatory requirements across European countries
- Limitations in replicating certain human disease conditions accurately
How This Report Can Add Value?
Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in transgenic animal model, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.
Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.
Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.
Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new transgenic animal model products.
Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.
Key Market Players and Competition Synopsis
Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- genOway
- Sigma-Aldrich Co. (Merck Group)
- Janvier Group
Table of Contents
Executive Summary
Scope and Definition
1 Market: Industry Outlook
- 1.1 Market Overview
- 1.1.1 Market Overview and Ecosystem
- 1.2 Market Trends
- 1.2.1 Impact Analysis
- 1.2.2 Rising Demand for Personalized Medicine
- 1.3 Regulatory Landscape
- 1.3.1 Europe
- 1.3.1.1 Germany
- 1.3.1.2 U.K.
- 1.3.1 Europe
- 1.4 Pricing Analysis
- 1.4.1 Generation Costs (Creating New Models)
- 1.4.2 Acquisition Costs (Purchasing Existing Models)
- 1.4.3 Additional Costs
- 1.5 Technology Landscape
- 1.6 Market Dynamics
- 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
- 1.6.2 Market Drivers
- 1.6.2.1 Growing Number of Pharmaceutical Research and Drug Development Activities
- 1.6.2.2 Technological Advancements in Genetic Engineering
- 1.6.2.3 Increasing Demand for Advanced Disease Models for Drug Discovery
- 1.6.3 Market Restraints
- 1.6.3.1 High Maintenance Cost of Animal Models
- 1.6.3.2 Strict Regulations and Guidelines
- 1.6.4 Market Opportunities
- 1.6.4.1 Emergence of CRISPR as a Powerful Tool for Biomedical Research Field
- 1.6.4.2 Increasing Demand for Disease-Specific Models
2 Region
- 2.1 Regional Summary
- 2.2 Europe
- 2.2.1 Regional Overview
- 2.2.2 Driving Factors for Market Growth
- 2.2.3 Factors Challenging the Market
- 2.2.4 Market Sizing and Forecast
- 2.2.4.1 Europe Transgenic Animal Model Market, by Technology
- 2.2.4.2 Europe Transgenic Animal Model Market, by Animal Type
- 2.2.4.3 Europe Transgenic Animal Model Market, by Application
- 2.2.4.4 Europe Transgenic Animal Model Market, by End User
- 2.2.4.5 Europe Transgenic Animal Model Market, by Country
- 2.2.5 U.K.
- 2.2.5.1 Country Overview
- 2.2.5.2 U.K. Transgenic Animal Model Market, by Technology
- 2.2.5.3 U.K. Transgenic Animal Model Market, by Animal Type
- 2.2.5.4 U.K. Transgenic Animal Model Market, by Application
- 2.2.5.5 U.K. Transgenic Animal Model Market, by End User
- 2.2.6 Germany
- 2.2.6.1 Country Overview
- 2.2.6.2 Germany Transgenic Animal Model Market, by Technology
- 2.2.6.3 Germany Transgenic Animal Model Market, by Animal Type
- 2.2.6.4 Germany Transgenic Animal Model Market, by Application
- 2.2.6.5 Germany Transgenic Animal Model Market, by End User
- 2.2.7 France
- 2.2.7.1 Country Overview
- 2.2.7.2 France Transgenic Animal Model Market, by Technology
- 2.2.7.3 France Transgenic Animal Model Market, by Animal Type
- 2.2.7.4 France Transgenic Animal Model Market, by Application
- 2.2.7.5 France Transgenic Animal Model Market, by End User
- 2.2.8 Italy
- 2.2.8.1 Country Overview
- 2.2.8.2 Italy Transgenic Animal Model Market, by Technology
- 2.2.8.3 Italy Transgenic Animal Model Market, by Animal Type
- 2.2.8.4 Italy Transgenic Animal Model Market, by Application
- 2.2.8.5 Italy Transgenic Animal Model Market, by End User
- 2.2.9 Spain
- 2.2.9.1 Country Overview
- 2.2.9.2 Spain Transgenic Animal Model Market, by Technology
- 2.2.9.3 Spain Transgenic Animal Model Market, by Animal Type
- 2.2.9.4 Spain Transgenic Animal Model Market, by Application
- 2.2.9.5 Spain Transgenic Animal Model Market, by End User
- 2.2.10 Rest-of-the- Europe
- 2.2.10.1 Country Overview
- 2.2.10.2 Rest of the Europe Transgenic Animal Model Market, by Technology
- 2.2.10.3 Rest of the Europe Transgenic Animal Model Market, by Animal Type
- 2.2.10.4 Rest of the Europe Transgenic Animal Model Market, by Application
- 2.2.10.5 Rest of the Europe Transgenic Animal Model Market, by End User
3 Competitive Benchmarking and Company Profiles
- 3.1 Company Profiles
- 3.1.1 genOway
- 3.1.1.1 Overview
- 3.1.2 Sigma-Aldrich Co. (Merck Group)
- 3.1.2.1 Overview
- 3.1.3 Janvier Group (Janvier Labs)
- 3.1.3.1 Overview
- 3.1.1 genOway
4 Research Methodology
- 4.1 Data Sources
- 4.1.1 Primary Data Sources
- 4.1.2 Secondary Data Sources
- 4.1.3 Inclusion and Exclusion
- 4.1.4 Data Triangulation
- 4.2 Market Estimation and Forecast
List of Figures
- Figure 1: Europe Transgenic Animal Model Market (by Scenario), $Million, 2024, 2028, and 2035
- Figure 2: Europe Transgenic Animal Model Market, 2024 and 2035
- Figure 3: Europe Transgenic Animal Model Market Snapshot
- Figure 4: Transgenic Animal Model Market, $Million, 2024 and 2035
- Figure 5: Europe Transgenic Animal Model Market (by Technology), $Million, 2024, 2028, and 2035
- Figure 6: Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024, 2028, and 2035
- Figure 7: Europe Transgenic Animal Model Market (by Application), $Million, 2024, 2028, and 2035
- Figure 8: Europe Transgenic Animal Model Market (by End User), $Million, 2024, 2028, and 2035
- Figure 9: Europe Transgenic Animal Model Market Segmentation
- Figure 10: Key Stakeholders of Transgenic Animal Model Market
- Figure 11: Transgenic Animals: Timeline of Key Events
- Figure 12: Role of Humanized Mouse Models in Development of New Precision and Personalized Medicine Strategies
- Figure 13: Regulatory Bodies of Transgenic Animals in Europe
- Figure 14: Regulatory Bodies of Transgenic Animals in Germany
- Figure 15: Regulatory Process
- Figure 16: Evolution of Transgenic Technologies
- Figure 17: Europe Drug Development Pipeline, 2019 and 2024
- Figure 18: Major Technical Advances in Genome Editing and Delivery in Mice and Rats from 1980s to 2020s
- Figure 19: Europe Transgenic Animal Model Market, $Million, 2024-2035
- Figure 20: Inclusion and Exclusion Criteria for Europe Transgenic Animal Model Market
- Figure 21: Data Triangulation
- Figure 22: Top-Down and Bottom-Up Approach
- Figure 23: Assumptions and Limitations
List of Tables
- Table 1: Market Snapshot
- Table 2: Cost of Generating New Transgenic Animals
- Table 3: Cost of Purchasing Existing Models
- Table 4: Additional Costs
- Table 5: Transgenic Animal Model Market (by Region), $Million, 2024-2035
- Table 6: Europe Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 7: Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 8: Europe Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 9: Europe Transgenic Animal Model Market (by End User), $Million, 2024-2035
- Table 10: Europe Transgenic Animal Model Market (by Country), $Million, 2024-2035
- Table 11: U.K. Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 12: U.K. Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 13: U.K. Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 14: U.K. Transgenic Animal Model Market (by End User), $Million, 2024-2035
- Table 15: Germany Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 16: Germany Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 17: Germany Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 18: Germany Transgenic Animal Model Market (by End User), $Million, 2024-2035
- Table 19: France Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 20: France Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 21: France Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 22: France Transgenic Animal Model Market (by End User), $Million, 2024-2035
- Table 23: Italy Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 24: Italy Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 25: Italy Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 26: Italy Transgenic Animal Model Market (by End User), $Million, 2024-2035
- Table 27: Spain Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 28: Spain Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 29: Spain Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 30: Spain Transgenic Animal Model Market (by End User), $Million, 2024-2035
- Table 31: Rest of the Europe Transgenic Animal Model Market (by Technology), $Million, 2024-2035
- Table 32: Rest of the Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
- Table 33: Rest of the Europe Transgenic Animal Model Market (by Application), $Million, 2024-2035
- Table 34: Rest of the Europe Transgenic Animal Model Market (by End User), $Million, 2024-2035
